US20140044827A1 - Dietary supplement containing lyophilized dairy and linolenic acid - Google Patents

Dietary supplement containing lyophilized dairy and linolenic acid Download PDF

Info

Publication number
US20140044827A1
US20140044827A1 US13/963,016 US201313963016A US2014044827A1 US 20140044827 A1 US20140044827 A1 US 20140044827A1 US 201313963016 A US201313963016 A US 201313963016A US 2014044827 A1 US2014044827 A1 US 2014044827A1
Authority
US
United States
Prior art keywords
oil
dietary supplement
combination
lyophilized
linolenic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/963,016
Inventor
Shawn Mitchell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fitletic Wellness LLC
Original Assignee
Bodygenex LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bodygenex LLC filed Critical Bodygenex LLC
Priority to US13/963,016 priority Critical patent/US20140044827A1/en
Assigned to Bodygenex LLC reassignment Bodygenex LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MITCHELL, SHAWN
Publication of US20140044827A1 publication Critical patent/US20140044827A1/en
Priority to US15/626,304 priority patent/US20170280739A1/en
Assigned to FITLETIC WELLNESS, LLC reassignment FITLETIC WELLNESS, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BODYGENEX, LLC
Priority to US16/183,770 priority patent/US10893684B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00Milk preparations; Milk powder or milk powder preparations
    • A23C9/152Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/1528Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C13/00Cream; Cream preparations; Making thereof
    • A23C13/12Cream preparations
    • A23C13/125Cream preparations in powdered, granulated or solid form
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C19/00Cheese; Cheese preparations; Making thereof
    • A23C19/06Treating cheese curd after whey separation; Products obtained thereby
    • A23C19/068Particular types of cheese
    • A23C19/076Soft unripened cheese, e.g. cottage or cream cheese
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00Milk preparations; Milk powder or milk powder preparations
    • A23C9/12Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • A23C9/1315Non-milk proteins or fats; Seeds, pulses, cereals or soja; Fatty acids, phospholipids, mono- or diglycerides or derivatives therefrom; Egg products
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00Milk preparations; Milk powder or milk powder preparations
    • A23C9/152Milk preparations; Milk powder or milk powder preparations containing additives

Definitions

  • linolenic acid refers to the two octadecatrienoic acids ⁇ -linolenic acid (an omega-3 fatty acid) and ⁇ -linolenic acid (an omega-6 fatty acid), as well as esters thereof (such as acyl-linolenates, for example triglyceride esters of linolenic acid, and the like).
  • esters thereof such as acyl-linolenates, for example triglyceride esters of linolenic acid, and the like.
  • linolenic acids per se are carboxylic acids with 18-carbon chains and three cis double bonds:
  • Linolenic acid is a fatty acid found primarily in vegetable oils. It is sold as a dietary supplement for use in humans, principally for treating problems with inflammation and auto-immune diseases. Its efficacy to treat such ailments, however, is disputed.
  • the patent literature describes at least one medicinal use of linolenic acid. See U.S. Pat. No. 7,935,729, issued May 3, 2011, to Harbige et al. Harbige et al. describe treating neurodegenerative diseases by administering to a patient a triglyceride oil containing both ⁇ -linolenic acid and linolenic acid residues as triglyceride ester.
  • the ratio of ⁇ -linolenic acid to linolenic acid residues at the sn-2 position of the triglyceride is at least 0.8.
  • the amount of ⁇ -linolenic acid residues at the sn-2 position is at least 18%.
  • the oil is administered at a dose sufficient to maintain or elevate TGF- ⁇ 1 levels in the patient at a therapeutic level.
  • a dietary supplement comprising a lyophilized dairy component, such as lyophilized cream, whole milk, reduced fat milk, cottage cheese, yogurt, and combinations thereof, which is physically combined into a mixture with an oil comprising linolenic acid, and/or esters of linolenic acid, and/or a non-toxic salt of linoleic acid, and/or a mixture thereof.
  • a lyophilized dairy component such as lyophilized cream, whole milk, reduced fat milk, cottage cheese, yogurt, and combinations thereof, which is physically combined into a mixture with an oil comprising linolenic acid, and/or esters of linolenic acid, and/or a non-toxic salt of linoleic acid, and/or a mixture thereof.
  • Preferred versions of the supplement contain ⁇ -linolenic acid and/or its esters and/or salts.
  • Numerical ranges as used herein are intended to include every number and subset of numbers contained within that range, whether specifically disclosed or not. Further, these numerical ranges should be construed as providing support for a claim directed to any number or subset of numbers in that range. For example, a disclosure of from 1 to 10 should be construed as supporting a range of from 2 to 8, from 3 to 7, from 1 to 9, from 3.6 to 4.6, from 3.5 to 9.9, and so forth.
  • the methods of the present invention can comprise, consist of, or consist essentially of the essential elements and limitations of the products and methods described herein, as well as any additional or optional ingredients, components, or limitations described herein or otherwise useful in formulating dietary supplements.
  • drying refers to any method now known in the art or developed in the future to convert a liquid product into a corresponding dried product
  • drying the dairy product can be accomplished by, for example (and not limitation) evaporation, freeze-drying (i.e., lyophilization or cryodesiccation), spray drying, and the like.
  • the dried dairy component is then physically combined with one or more oils comprising linolenic acid and/or its esters.
  • the preferred oils are selected from the group consisting of safflower oil, grape seed oil, poppy seed oil, sunflower oil, hemp oil, corn oil, wheat germ oil, cottonseed oil, soybean oil, walnut oil, sesame oil, rice bran oil, pistachio oil, peanut oil, canola oil, flaxseed oil (linseed oil), olive oil, palm oil, cocoa butter, macadamia oil, butter, coconut oil, and combinations thereof.
  • the combination is a heterogeneous mixture of the dried dairy component and the liquid (or semi-liquid) oil component.
  • the resulting combination may optionally be presented in unit dosage form.
  • the oil too may be dried, so that the combination is in homogeneous powder mixture.
  • cottage cheese is used broadly to designate any type of fresh cheese curd, whether curdled with rennet, or added acid, or heat, or a combination of all three.
  • cottage cheese includes traditional, U.S.-style cottage cheese (which is typically curdled with rennet) as well as fresh cheese such as quark (made by warming soured milk until the desired degree of denaturation of milk proteins is met, and then strained), fromage frais, fresh chudder, and the like.
  • the milk product need not come from cows, but from any dairy source, such as goats, sheep, etc.
  • the dietary supplement be presented in unit dosage form, such as capsules or tablets.
  • the dietary supplement may be manufactured in unit dosage form and may be prepared by any of the methods well-known in the art of the formulation of foods and pharmaceuticals. All methods include the step of bringing the active compounds into association with one another and optional ingredients, such as carriers, accessory ingredients, and the like. In general, the formulations are prepared by uniformly and intimately bringing the dried dairy and oil components into association with one another and then, if necessary, shaping the product into desired unit dosage form.
  • the recommended in vivo dosage in humans and other mammals depends largely upon the age and general health of the patient being treated. Determining the optimum dosage for any given mammal is essentially an empirical and ongoing process.
  • the dietary supplement is administered orally. Because of the differences in ages, size and nature of animals, including humans, the amounts which are safe and effective to improve and maintain the health of any given individual may vary considerably. Linolenic acid is a natural food ingredient and it is relatively non-toxic. Thus, the dosages that can be administered in the method disclosed herein are not overly critical as long as they are enough to be effective to maintain the overall nutritional health of the individual being treated, and not so high as to induce a fat intake-related disorder, such as a lipidosis.
  • Tablets are made by compression or molding, optionally with one or more accessory ingredients.
  • Compressed tablets are prepared by compressing the active compound in a free-flowing form, e.g., a powder or granules, optionally mixed with accessory ingredients, e.g., binders, lubricants, inert diluents, surface active or dispersing agents, using conventional tabletting machinery.
  • Molded tablets may be made by molding a mixture of the combination neat or with a suitable carrier, again using conventional and well-known molding equipment.
  • the formulations of this invention may further include one or more optional accessory ingredient(s) utilized in the art of dietary formulations, e.g., diluents, buffers, flavoring agents, colorants, binders, surface active agents, thickeners, lubricants, suspending agents, preservatives (including anti-oxidants) and the like.
  • optional accessory ingredient(s) utilized in the art of dietary formulations, e.g., diluents, buffers, flavoring agents, colorants, binders, surface active agents, thickeners, lubricants, suspending agents, preservatives (including anti-oxidants) and the like.
  • the dosage may also be carried within an orally tolerated capsule, such as a Caplique-brand capsule.
  • a suitable effective dose for most conditions ranges from about 1 mg/kg body weight to about 10 g/kg body weight per day, and is preferably in the range of from about 10 to about 1000 mg/kg body weight per day, or about 100 to about 500 mg/kg body weight per day.
  • the total daily dose may be given as a single dose, multiple doses, e.g., two to six times per day, or by intravenous infusion for a selected duration. Dosages above or below the above-cited ranges are within the scope of the invention and such dosages may be administered to individual subject if the circumstances so dictate.
  • a typical daily dosage might fall with the range of from about 100 mg to about 100 g per day. If discrete multiple doses are indicated, treatment might typically comprise 4 equal fractional doses given at 8 hour intervals to supply the total daily dosage.
  • Also disclosed herein is a method of improving the nutritional status of a mammal, including a human, comprising administering to the mammal a dosage of from about 1 mg/kg body weight to about 10 g/kg body weight per day of a dietary supplement comprising, in combination a dried dairy product, wherein the dairy product is selected from the group consisting of cream, whole milk, reduced fat milk, cottage cheese, yogurt, and combinations thereof; in combination with an oil comprising linolenic acid.
  • the administered supplement comprises lyophilized cottage cheese, yogurt, or a combination thereof; in combination with flaxseed oil (linseed oil).
  • the formulation may explicitly exclude components found naturally in dairy products, such as lactose.
  • a dietary supplement consisting essentially of or consisting exclusively of, in combination, a dried dairy product, wherein the dairy product is selected from the group consisting of cream, whole milk, reduced fat milk, cottage cheese, yogurt, and combinations thereof, wherein the dried dairy product is devoid of lactose or has a reduced lactose concentration as compared to its natural state; in combination with linolenic acid.
  • a reduced lactose concentration as compared to its natural state means that at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90% of the lactose naturally found in the dried dairy product is removed from the dried dairy product before the dried dairy product is admixed with the linolenic acid.
  • the ultimate composition has a reduced lactose concentration.
  • a dietary supplement consisting essentially of or consisting of, in combination: (a) lyophilized cottage cheese, yogurt, or a combination thereof, in which at least 50% of naturally occurring lactose has been removed; in combination with (b) flaxseed oil (linseed oil).
  • a dietary supplement consisting essentially of or consisting of, in combination: (a) a dried dairy product, wherein the dairy product is selected from the group consisting of cream, whole milk, reduced fat milk, cottage cheese, yogurt, and combinations thereof, in which at least 50% of naturally occurring lactose has been removed; in combination with (b) linolenic acid.
  • compositions described herein are useful as dietary supplements to improve and maintain the nutritional health of humans and other mammals.
  • the compositions described herein may be formulated in unit dosages suitable for human and/or veterinarian uses.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Dairy Products (AREA)

Abstract

Described is a dietary supplement and a corresponding method to maintain the nutritional health of mammals, including humans. The composition includes a dried dairy product, typically cream, whole milk, reduced fat milk, cottage cheese, yogurt, or combinations thereof in combination with an oil comprising linolenic acid.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • Priority is hereby claimed to provisional application Ser. No. 61/681,935, filed Aug. 10, 2012, which is incorporated herein by reference
  • BACKGROUND
  • As used herein, “linolenic acid” refers to the two octadecatrienoic acids α-linolenic acid (an omega-3 fatty acid) and γ-linolenic acid (an omega-6 fatty acid), as well as esters thereof (such as acyl-linolenates, for example triglyceride esters of linolenic acid, and the like). In short, linolenic acids per se are carboxylic acids with 18-carbon chains and three cis double bonds:
  • Figure US20140044827A1-20140213-C00001
  • Linolenic acid is a fatty acid found primarily in vegetable oils. It is sold as a dietary supplement for use in humans, principally for treating problems with inflammation and auto-immune diseases. Its efficacy to treat such ailments, however, is disputed.
  • The patent literature describes at least one medicinal use of linolenic acid. See U.S. Pat. No. 7,935,729, issued May 3, 2011, to Harbige et al. Harbige et al. describe treating neurodegenerative diseases by administering to a patient a triglyceride oil containing both γ-linolenic acid and linolenic acid residues as triglyceride ester. The ratio of γ-linolenic acid to linolenic acid residues at the sn-2 position of the triglyceride is at least 0.8. The amount of γ-linolenic acid residues at the sn-2 position is at least 18%. The oil is administered at a dose sufficient to maintain or elevate TGF-β1 levels in the patient at a therapeutic level.
  • DETAILED DESCRIPTION
  • Disclosed herein is a dietary supplement comprising a lyophilized dairy component, such as lyophilized cream, whole milk, reduced fat milk, cottage cheese, yogurt, and combinations thereof, which is physically combined into a mixture with an oil comprising linolenic acid, and/or esters of linolenic acid, and/or a non-toxic salt of linoleic acid, and/or a mixture thereof. Preferred versions of the supplement contain α-linolenic acid and/or its esters and/or salts.
  • Numerical ranges as used herein are intended to include every number and subset of numbers contained within that range, whether specifically disclosed or not. Further, these numerical ranges should be construed as providing support for a claim directed to any number or subset of numbers in that range. For example, a disclosure of from 1 to 10 should be construed as supporting a range of from 2 to 8, from 3 to 7, from 1 to 9, from 3.6 to 4.6, from 3.5 to 9.9, and so forth.
  • All references to singular characteristics or limitations of the present invention shall include the corresponding plural characteristic or limitation, and vice-versa, unless otherwise specified or clearly implied to the contrary by the context in which the reference is made.
  • All combinations of method or process steps as used herein can be performed in any order, unless otherwise specified or clearly implied to the contrary by the context in which the referenced combination is made.
  • The methods of the present invention can comprise, consist of, or consist essentially of the essential elements and limitations of the products and methods described herein, as well as any additional or optional ingredients, components, or limitations described herein or otherwise useful in formulating dietary supplements.
  • One step in preparing the dietary supplement is to dry a suitable dairy component for use in the product. As used herein, the term “dry” or “drying” refers to any method now known in the art or developed in the future to convert a liquid product into a corresponding dried product Thus, as used herein, drying the dairy product can be accomplished by, for example (and not limitation) evaporation, freeze-drying (i.e., lyophilization or cryodesiccation), spray drying, and the like.
  • The dried dairy component is then physically combined with one or more oils comprising linolenic acid and/or its esters. The preferred oils are selected from the group consisting of safflower oil, grape seed oil, poppy seed oil, sunflower oil, hemp oil, corn oil, wheat germ oil, cottonseed oil, soybean oil, walnut oil, sesame oil, rice bran oil, pistachio oil, peanut oil, canola oil, flaxseed oil (linseed oil), olive oil, palm oil, cocoa butter, macadamia oil, butter, coconut oil, and combinations thereof. Thus, the combination is a heterogeneous mixture of the dried dairy component and the liquid (or semi-liquid) oil component.
  • The resulting combination may optionally be presented in unit dosage form.
  • In another version of the supplement, the oil too may be dried, so that the combination is in homogeneous powder mixture.
  • As used herein, the term cottage cheese is used broadly to designate any type of fresh cheese curd, whether curdled with rennet, or added acid, or heat, or a combination of all three. For example, cottage cheese includes traditional, U.S.-style cottage cheese (which is typically curdled with rennet) as well as fresh cheese such as quark (made by warming soured milk until the desired degree of denaturation of milk proteins is met, and then strained), fromage frais, fresh chèvre, and the like. The milk product need not come from cows, but from any dairy source, such as goats, sheep, etc.
  • It is preferred that the dietary supplement be presented in unit dosage form, such as capsules or tablets. Thus, the dietary supplement may be manufactured in unit dosage form and may be prepared by any of the methods well-known in the art of the formulation of foods and pharmaceuticals. All methods include the step of bringing the active compounds into association with one another and optional ingredients, such as carriers, accessory ingredients, and the like. In general, the formulations are prepared by uniformly and intimately bringing the dried dairy and oil components into association with one another and then, if necessary, shaping the product into desired unit dosage form.
  • The recommended in vivo dosage in humans and other mammals depends largely upon the age and general health of the patient being treated. Determining the optimum dosage for any given mammal is essentially an empirical and ongoing process. The dietary supplement is administered orally. Because of the differences in ages, size and nature of animals, including humans, the amounts which are safe and effective to improve and maintain the health of any given individual may vary considerably. Linolenic acid is a natural food ingredient and it is relatively non-toxic. Thus, the dosages that can be administered in the method disclosed herein are not overly critical as long as they are enough to be effective to maintain the overall nutritional health of the individual being treated, and not so high as to induce a fat intake-related disorder, such as a lipidosis.
  • Tablets are made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets are prepared by compressing the active compound in a free-flowing form, e.g., a powder or granules, optionally mixed with accessory ingredients, e.g., binders, lubricants, inert diluents, surface active or dispersing agents, using conventional tabletting machinery. Molded tablets may be made by molding a mixture of the combination neat or with a suitable carrier, again using conventional and well-known molding equipment.
  • In addition to the aforementioned ingredients, the formulations of this invention may further include one or more optional accessory ingredient(s) utilized in the art of dietary formulations, e.g., diluents, buffers, flavoring agents, colorants, binders, surface active agents, thickeners, lubricants, suspending agents, preservatives (including anti-oxidants) and the like.
  • The dosage may also be carried within an orally tolerated capsule, such as a Caplique-brand capsule.
  • A suitable effective dose for most conditions ranges from about 1 mg/kg body weight to about 10 g/kg body weight per day, and is preferably in the range of from about 10 to about 1000 mg/kg body weight per day, or about 100 to about 500 mg/kg body weight per day. The total daily dose may be given as a single dose, multiple doses, e.g., two to six times per day, or by intravenous infusion for a selected duration. Dosages above or below the above-cited ranges are within the scope of the invention and such dosages may be administered to individual subject if the circumstances so dictate.
  • For example, in a 75 kg mammal, a typical daily dosage might fall with the range of from about 100 mg to about 100 g per day. If discrete multiple doses are indicated, treatment might typically comprise 4 equal fractional doses given at 8 hour intervals to supply the total daily dosage.
  • Also disclosed herein is a method of improving the nutritional status of a mammal, including a human, comprising administering to the mammal a dosage of from about 1 mg/kg body weight to about 10 g/kg body weight per day of a dietary supplement comprising, in combination a dried dairy product, wherein the dairy product is selected from the group consisting of cream, whole milk, reduced fat milk, cottage cheese, yogurt, and combinations thereof; in combination with an oil comprising linolenic acid. In the preferred version of the method, the administered supplement comprises lyophilized cottage cheese, yogurt, or a combination thereof; in combination with flaxseed oil (linseed oil).
  • In some versions of the product and corresponding method, the formulation may explicitly exclude components found naturally in dairy products, such as lactose. Thus, also disclosed herein is a dietary supplement consisting essentially of or consisting exclusively of, in combination, a dried dairy product, wherein the dairy product is selected from the group consisting of cream, whole milk, reduced fat milk, cottage cheese, yogurt, and combinations thereof, wherein the dried dairy product is devoid of lactose or has a reduced lactose concentration as compared to its natural state; in combination with linolenic acid.
  • In this context, the phrase “a reduced lactose concentration as compared to its natural state” means that at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90% of the lactose naturally found in the dried dairy product is removed from the dried dairy product before the dried dairy product is admixed with the linolenic acid. In this fashion, the ultimate composition has a reduced lactose concentration. Thus, for example, disclosed herein is a dietary supplement consisting essentially of or consisting of, in combination: (a) lyophilized cottage cheese, yogurt, or a combination thereof, in which at least 50% of naturally occurring lactose has been removed; in combination with (b) flaxseed oil (linseed oil). Or, for example, a dietary supplement consisting essentially of or consisting of, in combination: (a) a dried dairy product, wherein the dairy product is selected from the group consisting of cream, whole milk, reduced fat milk, cottage cheese, yogurt, and combinations thereof, in which at least 50% of naturally occurring lactose has been removed; in combination with (b) linolenic acid.
  • It has been found, quite unexpectedly, that the combination of dairy and linolenic acid greatly improves the general nutritional health and metabolism of mammals, including humans. Thus, the composition and method described herein are useful as dietary supplements to improve and maintain the nutritional health of humans and other mammals. The compositions described herein may be formulated in unit dosages suitable for human and/or veterinarian uses.

Claims (15)

What is claimed is:
1. A dietary supplement comprising, in combination:
(a) a dried dairy product, wherein the dairy product is selected from the group consisting of cream, whole milk, reduced fat milk, cottage cheese, yogurt, and combinations thereof; in combination with
(b) an oil comprising linolenic acid.
2. The dietary supplement according to claim 1, wherein the oil is lyophilized.
3. The dietary supplement according to claim 1, in unit dosage form.
4. The dietary supplement of claim 1, wherein the oil is selected from the group consisting of safflower oil, grape seed oil, poppy seed oil, sunflower oil, hemp oil, corn oil, wheat germ oil, cottonseed oil, soybean oil, walnut oil, sesame oil, rice bran oil, pistachio oil, peanut oil, canola oil, flaxseed oil (linseed oil), olive oil, palm oil, cocoa butter, macadamia oil, butter, coconut oil, and combinations thereof.
5. The dietary supplement according to claim 4, wherein the oil is lyophilized.
5. The dietary supplement according to claim 4, in unit dosage form.
7. The dietary supplement of claim 1, wherein the oil comprises flaxseed oil (linseed oil).
8. The dietary supplement according to claim 7, wherein the oil is lyophilized.
9. The dietary supplement according to claim 7, in unit dosage form.
10. A dietary supplement comprising, in combination:
(a) lyophilized cottage cheese, yogurt, or a combination thereof; in combination with
(b) flaxseed oil (linseed oil).
11. A method of improving the nutritional status of a mammal, including a human, comprising administering to the mammal a dosage of from about 1 mg/kg body weight to about 10 g/kg body weight per day of a dietary supplement comprising, in combination:
(a) a dried dairy product, wherein the dairy product is selected from the group consisting of cream, whole milk, reduced fat milk, cottage cheese, yogurt, and combinations thereof; in combination with
(b) an oil comprising linolenic acid.
12. The method according to claim 11, wherein the oil is lyophilized.
13. The method according to claim 11, in unit dosage form.
14. The method according to claim 11, wherein the oil is selected from the group consisting of safflower oil, grape seed oil, poppy seed oil, sunflower oil, hemp oil, corn oil, wheat germ oil, cottonseed oil, soybean oil, walnut oil, sesame oil, rice bran oil, pistachio oil, peanut oil, canola oil, flaxseed oil (linseed oil), olive oil, palm oil, cocoa butter, macadamia oil, butter, coconut oil, and combinations thereof.
15. A method of improving the nutritional status of a mammal, including a human, comprising administering to the mammal a dosage of from about 1 mg/kg body weight to about 10 g/kg body weight per day of a dietary supplement comprising, in combination:
(a) lyophilized cottage cheese, yogurt, or a combination thereof; in combination with
(b) flaxseed oil (linseed oil).
US13/963,016 2012-08-10 2013-08-09 Dietary supplement containing lyophilized dairy and linolenic acid Abandoned US20140044827A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US13/963,016 US20140044827A1 (en) 2012-08-10 2013-08-09 Dietary supplement containing lyophilized dairy and linolenic acid
US15/626,304 US20170280739A1 (en) 2012-08-10 2017-06-19 Dietary Supplement Containing Lyophilized Diary and Linolenic Acid
US16/183,770 US10893684B2 (en) 2012-08-10 2018-11-08 Dietary supplement containing lyophilized dairy and linolenic acid

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261681935P 2012-08-10 2012-08-10
US13/963,016 US20140044827A1 (en) 2012-08-10 2013-08-09 Dietary supplement containing lyophilized dairy and linolenic acid

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/626,304 Division US20170280739A1 (en) 2012-08-10 2017-06-19 Dietary Supplement Containing Lyophilized Diary and Linolenic Acid

Publications (1)

Publication Number Publication Date
US20140044827A1 true US20140044827A1 (en) 2014-02-13

Family

ID=50066338

Family Applications (3)

Application Number Title Priority Date Filing Date
US13/963,016 Abandoned US20140044827A1 (en) 2012-08-10 2013-08-09 Dietary supplement containing lyophilized dairy and linolenic acid
US15/626,304 Abandoned US20170280739A1 (en) 2012-08-10 2017-06-19 Dietary Supplement Containing Lyophilized Diary and Linolenic Acid
US16/183,770 Active 2033-12-13 US10893684B2 (en) 2012-08-10 2018-11-08 Dietary supplement containing lyophilized dairy and linolenic acid

Family Applications After (2)

Application Number Title Priority Date Filing Date
US15/626,304 Abandoned US20170280739A1 (en) 2012-08-10 2017-06-19 Dietary Supplement Containing Lyophilized Diary and Linolenic Acid
US16/183,770 Active 2033-12-13 US10893684B2 (en) 2012-08-10 2018-11-08 Dietary supplement containing lyophilized dairy and linolenic acid

Country Status (1)

Country Link
US (3) US20140044827A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4034123A (en) * 1976-02-13 1977-07-05 The United States Of America As Represented By The Secretary Of The Army Compressed, freeze-dried cottage cheese and method of making
US5393551A (en) * 1991-09-06 1995-02-28 Jersey Farms Corp. Modified milk containing a butter fat substitute which includes partially hydrogenated soybean oil
US6010719A (en) * 1997-09-16 2000-01-04 Universiteit Gent Freeze-dried disintegrating tablets
US20130280377A1 (en) * 2010-12-29 2013-10-24 Judith Arfsten Use of encapsulated oil in dough preparation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0311081D0 (en) 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4034123A (en) * 1976-02-13 1977-07-05 The United States Of America As Represented By The Secretary Of The Army Compressed, freeze-dried cottage cheese and method of making
US5393551A (en) * 1991-09-06 1995-02-28 Jersey Farms Corp. Modified milk containing a butter fat substitute which includes partially hydrogenated soybean oil
US6010719A (en) * 1997-09-16 2000-01-04 Universiteit Gent Freeze-dried disintegrating tablets
US20130280377A1 (en) * 2010-12-29 2013-10-24 Judith Arfsten Use of encapsulated oil in dough preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RECOMMENDED DIETARY ALLOWANCES (RDAs), p. 1-2, National Academy of Sciences, 1997, http://users.rcn.com/jkimball.ma.ultranet/BiologyPages/R/RDAs.html. *

Also Published As

Publication number Publication date
US20190069570A1 (en) 2019-03-07
US20170280739A1 (en) 2017-10-05
US10893684B2 (en) 2021-01-19

Similar Documents

Publication Publication Date Title
TWI432147B (en) Dietary supplements for promotion of growth, repair, and maintenance of bone and joints
AU2001273028B2 (en) Improved methods of incorporating polyunsaturated fatty acids in milk
US11638434B2 (en) Feed additive compositions
US20190116833A1 (en) Feed additive compositions
AU2001273028A1 (en) Improved methods of incorporating polyunsaturated fatty acids in milk
US20220338504A1 (en) Feed additive compositions
EP3709808A1 (en) Compositions and methods of improving dietary phosphorus and calcium utilization in animals
US20170035721A1 (en) Composition for preventing or improving peripheral neuropathy
Joshi et al. Indian cow and A2 beta-casein–A scientific perspective on health benefits
US10893684B2 (en) Dietary supplement containing lyophilized dairy and linolenic acid
AU8828798A (en) Dairy products with enhanced cla content
JP2015535822A (en) Plant phenol and its use in the treatment or prevention of eosinophilic esophagitis
CN110037177B (en) Milk cow feed additive and preparation and use methods thereof
Mordenti et al. Effect of feeding whole soybean and linseed on milk and Parmigiano Reggiano cheese lipid fraction
KR20210076409A (en) Greek yogurt composition balanced with omega fatty acids and preparation method thereof
WO2019146735A1 (en) Composition for preventing or improving nociceptive pain
JP7356833B2 (en) Peripheral thermostimulant
JP6038416B1 (en) Fire suppression agent
JP6280356B2 (en) Oral agent for hair growth and hair growth promotion
EP4337187A1 (en) Administration of baiba to increase benefit of losing weight of intermittent fasting
CN113660866A (en) Cow milk with high n 6-polyunsaturated fatty acid content
JP2023113819A (en) lipid combination
CA3240771A1 (en) Methods of improving the nutritional status of immune stressed animals
WO2008026334A1 (en) Agent for inhibiting intestinal permeation of allergen

Legal Events

Date Code Title Description
AS Assignment

Owner name: BODYGENEX LLC, WISCONSIN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MITCHELL, SHAWN;REEL/FRAME:030975/0135

Effective date: 20130808

AS Assignment

Owner name: FITLETIC WELLNESS, LLC, WISCONSIN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BODYGENEX, LLC;REEL/FRAME:043688/0572

Effective date: 20170926

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION